AIM ImmunoTech is trading at $0.25 (6.4% up) in pre-market, bouncing modestly after several sessions of low-priced, choppy trading with no clear fundamental catalyst identified.
- The gain appears to be a light-liquidity uptick rather than a reaction to new fundamental information.
- There are no fresh company-specific headlines, earnings, FDA decisions, or analyst calls tied directly to this move.